July 1, 2019
Comments Off on Autophagy facilitates the release of immunogenic signals following chemotherapy in 3D models of mesothelioma.
Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.
CONCLUSION: The complete absence of SV40 Tag mRNA in this large series of cases contradicts experimental evidence suggestive of SV40 link with asbestos-exposed malignant pleural mesotheliomas in the UK population. Alternative explanations of the negative findings are discussed to exclude possible confounding factors.June 28, 2019
Comments Off on Does Simian Virus 40 (SV40) Have a Role in UK Malignant Pleural Mesothelioma? No Role is Identified in a Sensitive RNA In Situ Hybridization Study on Potentially Affected Birth Cohorts.
Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting ‘Direct to LAT’ in selected groups.
A 'Direct-to-LAT' approach may be appropriate in this setting. No baseline predictors of incomplete cytology were identified.June 27, 2019
Comments Off on Baseline predictors of negative and incomplete pleural cytology in patients with suspected pleural malignancy – Data supporting ‘Direct to LAT’ in selected groups.
Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
CONCLUSION: Median serum MMP9 levels differed significantly before and after treatment of MM, but failed to reach significance as a standalone biomarker. The contribution of MMP9 serum levels and MMP9 polymorphisms to a composite diagnostic and prognostic biomarker should be further tested.June 26, 2019
Comments Off on Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma.
Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.
RESULTS: The results of this study will be submitted to a peer-reviewed journal for publication. CONCLUSION: This study will reanalyze the published data based on SRs to find a biomarker with the superior diagnostic performance for the diagnosis of MPM.June 25, 2019
Comments Off on Biomarkers for detecting malignant pleural mesothelioma: Protocol for a reanalysis of published data based on systematic reviews of diagnostic test accuracy.
The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.
CONCLUSION: This is the first study to describe the prevalence and clinical implications of non-expandable lung in mesothelioma. It demonstrated that NEL is a relatively common phenomenon that is associated with significant symptomatology and shorter survival.June 24, 2019
Comments Off on The Prevalence and Clinical Relevance of Non-expandable Lung in Malignant Pleural Mesothelioma: A Prospective, Single-Center Cohort Study of 229 Patients.
What is Mesothelioma?
Learn more about this fatal cancer, including the causes, symptoms, and treatments for both pleural and peritoneal tumors of the mesothelium at our parent site MesotheliomaCenter.
Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.
No survival advantage was observed for those with pathologic stage III or stage IV MPM, however. Our results justify the need for further prospective trials to investigate the utility of adjuvant radiotherapy among those with MPM.June 21, 2019
Comments Off on Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.
Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.
Of those who had a partial response, 9 (75%) had a high or moderate degree of ERβ expression in tumor cells, and 3 (25%) had a low or null degree of expression. CONCLUSIONS: High and moderate expression of ERβ group with advanced clinical stage malignant pleural mesothelioma was associated with a tendency of higher OS and better response to chemotherapy treatment resulting in longer PFS although statistical significance was not achieved.June 20, 2019
Comments Off on Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma.
Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Conclusions This study demonstrated that adding bevacizumab to standard chemotherapy in patients with advanced MPM had no negative impact on HRQoL. A significant improvement in the peripheral neuropathy and pain HRQoL dimensions was even observed.June 19, 2019
Comments Off on Health-related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial.
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Based on these results, mesothelin and fibulin-3 levels appear to be significantly lower in all control groups compared to those with MPM, making them good candidates for screening biomarkers. Osteopontin may be a useful biomarker for screening healthy individuals or those with benign lung disease, but would not be useful for screening patients with malignancies.June 18, 2019
Comments Off on Biomarkers for malignant pleural mesothelioma: a meta-analysis.